Last reviewed · How we verify
NCT06087991: BINDeR-TX
Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
trial testing Implementation of the BINDeR-Tx service model in Opioid Abuse in 65 participants. Completed in 1 October 2024.
1 October 2024
Quick facts
| Lead sponsor | Jerry Cochran |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 65 |
| Start date | 1 April 2023 |
| Primary completion | 1 October 2024 |
| Estimated completion | 1 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Implementation of the BINDeR-Tx service model
Conditions studied
- Opioid Abuse — all drugs for Opioid Abuse →
Sponsor
Jerry Cochran
Who can join
18 and older, any sex, with Opioid Abuse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Implementation of a rural emergency department-initiated buprenorphine program in the mountain west: a study protocol.
Seliski N, Madsen T, Eley S, Colosimo J, et al · · 2024 · cited 1× · PMID 39228007 · DOI 10.1186/s13722-024-00496-0
Verify or expand the search:
- PubMed search for NCT06087991
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Abuse
Currently open trials in the same condition.
- NCT05706311 — Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool · NA · active not recruiting
- NCT03773523 — Neuromodulation and Cognitive Training in Opioid Use Disorder · NA · recruiting
Other Jerry Cochran trials
Trials by the same sponsor.
- NCT05141266 — Healthy Opioid Prescription Engagement · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06087991 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jerry Cochran
- Last refreshed: 24 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06087991.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing